116 related articles for article (PubMed ID: 14977859)
1. Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.
Boyd DD; Wang H; Avila H; Parikh NU; Kessler H; Magdolen V; Gallick GE
Clin Cancer Res; 2004 Feb; 10(4):1545-55. PubMed ID: 14977859
[TBL] [Abstract][Full Text] [Related]
2. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade.
Lengyel E; Wang H; Gum R; Simon C; Wang Y; Boyd D
Oncogene; 1997 May; 14(21):2563-73. PubMed ID: 9191056
[TBL] [Abstract][Full Text] [Related]
3. The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU.
Kline CL; Irby RB
Apoptosis; 2011 Dec; 16(12):1285-94. PubMed ID: 21910008
[TBL] [Abstract][Full Text] [Related]
4. Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer.
Leupold JH; Asangani I; Maurer GD; Lengyel E; Post S; Allgayer H
Mol Cancer Res; 2007 May; 5(5):485-96. PubMed ID: 17510314
[TBL] [Abstract][Full Text] [Related]
5. The Kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells.
Wang H; Yang L; Jamaluddin MS; Boyd DD
J Biol Chem; 2004 May; 279(21):22674-83. PubMed ID: 15031282
[TBL] [Abstract][Full Text] [Related]
6. Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines.
Hudson MA; McReynold LM
Adv Exp Med Biol; 1999; 462():399-412. PubMed ID: 10599442
[TBL] [Abstract][Full Text] [Related]
7. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1.
Allgayer H; Wang H; Gallick GE; Crabtree A; Mazar A; Jones T; Kraker AJ; Boyd DD
J Biol Chem; 1999 Jun; 274(26):18428-37. PubMed ID: 10373450
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor beta-1 stimulates invasivity of hepatic stellate cells by engagement of the cell-associated fibrinolytic system.
Fibbi G; Pucci M; D'Alessio S; Grappone C; Pellegrini G; Salzano R; Casini A; Milani S; Del Rosso M
Growth Factors; 2001; 19(2):87-100. PubMed ID: 11769974
[TBL] [Abstract][Full Text] [Related]
12. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
[TBL] [Abstract][Full Text] [Related]
13. The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
Bartscht T; Lehnert H; Gieseler F; Ungefroren H
Cancer Chemother Pharmacol; 2012 Aug; 70(2):221-30. PubMed ID: 22699812
[TBL] [Abstract][Full Text] [Related]
14. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Hudson MA; McReynolds LM
J Natl Cancer Inst; 1997 May; 89(10):709-17. PubMed ID: 9168186
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
Ischenko I; Camaj P; Seeliger H; Kleespies A; Guba M; De Toni EN; Schwarz B; Graeb C; Eichhorn ME; Jauch KW; Bruns CJ
Oncogene; 2008 Dec; 27(57):7212-22. PubMed ID: 18794807
[TBL] [Abstract][Full Text] [Related]
16. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
Paciucci R; Torà M; Díaz VM; Real FX
Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules.
Gum R; Juarez J; Allgayer H; Mazar A; Wang Y; Boyd D
Oncogene; 1998 Jul; 17(2):213-25. PubMed ID: 9674706
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of urokinase-type plasminogen activator and its receptor in human gastric-cancer cell lines correlates with their invasiveness and tumorigenicity.
Park IK; Kim BJ; Goh YJ; Lyu MA; Park CG; Hwang ES; Kook YH
Int J Cancer; 1997 May; 71(5):867-73. PubMed ID: 9180158
[TBL] [Abstract][Full Text] [Related]
19. Over-expression of urokinase receptor in human epidermoid-carcinoma cell line (HEp3) increases tumorigenicity on chorio-allantoic membrane and in severe-combined-immunodeficient mice.
Lyu MA; Choi YK; Park BN; Kim BJ; Park IK; Hyun BH; Kook YH
Int J Cancer; 1998 Jul; 77(2):257-63. PubMed ID: 9650562
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors.
Leupold JH; Yang HS; Colburn NH; Asangani I; Post S; Allgayer H
Oncogene; 2007 Jul; 26(31):4550-62. PubMed ID: 17297470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
